Drug Trial Radar · NCT06225843
Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis
Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
17
Planned (sponsor's estimate)
Start
Feb 15, 2024
Primary completion
Mar 2026
Study completion Jun 2026
Sponsor
- Lead sponsor
- Alethia BiotherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase II study will recruit 17 colorectal cancer patients with liver-dominant metastases. All recruited patients will receive Sotevtamab at a dose of 800 mg once weekly for 6 cycles combined with FOLFOX once every 2 weeks for the first 4 cycles followed by liver metastases resection surgery with or without primary cancer resection. One cycle of treatment will consist of 14 days (2 weeks).
Conditions
- Metastatic Colorectal Cancer
Interventions
SotevtamabBiological
Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU)
FOLFOXCombination product
FOLFOX is a chemotherapy regimen for treatment of colorectal cancer, made up of the drugs folinic acid, fluorouracil, and oxaliplatin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rubbia-Brandt score at surgeryTime frame: 16-18 weeks
- Treatment-Emergent Adverse EventsTime frame: 14-16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.